Hunter Syndrome Market

In 2023, the United States represented the largest share of the Hunter Syndrome market across the 7MM, with approximately 500 prevalent cases. Available treatment options include enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and bone marrow transplantation (BMT). Currently, ELAPRASE is the only therapy approved by the FDA, whereas IZCARGO and HUNTERASE ICV have received approval in Japan. Despite these options, existing therapies fail to target cognitive symptoms due to the inability of ERTs to penetrate the blood–brain barrier. However, the pipeline landscape appears promising, with REGENXBIO’s RGX-121 progressing as a potential first-in-class gene therapy for MPS II, supported by FDA alignment on accelerated approval through surrogate biomarkers. Additionally, Denali Therapeutics’ DNL310 has shown encouraging interim Phase I/II data presented at the 2024 WORLD Symposium, demonstrating normalization of CSF heparan sulfate levels and a decline in neurofilament light chain (NfL).

DelveInsight’s report titled “Hunter Syndrome Market Insight, Epidemiology, and Market Forecast – 2036” offers an in-depth evaluation of the disease, including historical and forecasted epidemiology along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report provides insights into current treatment approaches, emerging therapies, drug market share, and projected market size from 2022 to 2036 across the seven major markets. It also outlines the treatment landscape, key market drivers and challenges, unmet needs, and growth prospects, delivering a forward-looking perspective on the Hunter Syndrome market.

To Know in detail about the Hunter Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Hunter Syndrome Market Forecast

Key Highlights from the Hunter Syndrome Market Report

• The United States is expected to maintain the largest Hunter Syndrome market size among the 7MM in 2025. The introduction of targeted emerging therapies is anticipated to transform treatment approaches and drive market expansion.
• In March 2026, Denali Therapeutics Inc. announced that the U.S. FDA granted accelerated approval to AVLAYAH™ (tividenofusp alfa-eknm), marking the first biologic therapy capable of crossing the blood-brain barrier and reaching systemic as well as neurological tissues. This enzyme replacement therapy is indicated for pediatric patients with Hunter syndrome (MPS II), both presymptomatic and symptomatic, weighing at least 5 kg prior to advanced neurological deterioration. Continued approval remains subject to confirmation of clinical benefits in subsequent trials.
• In February 2026, REGENXBIO Inc. reported that the FDA issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) of RGX-121 (clemidsogene lanparvovec) for MPS II, a rare neurodegenerative condition.
• In January 2026, Immusoft announced that its investigational therapy ISP-002 received Rare Pediatric Disease designation from the FDA for the treatment of MPS II (Hunter syndrome).
• In July 2025, Denali Therapeutics confirmed that the FDA accepted its BLA submission for tividenofusp alfa for accelerated approval in Hunter syndrome, granting Priority Review with a PDUFA target date of January 5, 2026.
• In May 2025, GC Biopharma revealed that Phase 3 clinical trial data for its investigational drug idursulfase beta (Hunterase) were published in the SCIE-indexed journal Genetics in Medicine.
• The diagnosed prevalent population of Hunter Syndrome across the 7MM was approximately 1,200 cases in 2025 and is expected to grow during the forecast period.
• In 2023, the EU4 and the United Kingdom accounted for nearly 350 diagnosed cases, with Germany reporting the highest number, followed by the UK.
• Leading companies in this space include Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Sangamo Therapeutics, ArmaGen, among others.
• Key emerging therapies include HMI-203, DNL310, RGX-121, SHP-609/TAK-609, and additional candidates in development.

Hunter Syndrome Overview

Hunter Syndrome, or Mucopolysaccharidosis II (MPS II), is a rare genetic lysosomal storage disorder resulting from a deficiency of the enzyme iduronate-2-sulfatase. This deficiency leads to the buildup of glycosaminoglycans (GAGs) within cells, tissues, and organs, causing progressive systemic damage. The condition predominantly affects males and presents with symptoms such as coarse facial features, hepatosplenomegaly, joint stiffness, respiratory complications, developmental delays, and in severe cases, cognitive decline. Current treatment approaches, including ERT and stem cell transplantation, help manage symptoms but do not provide a cure. Gene therapy approaches are currently under active investigation.

Discover Hunter Syndrome market drivers, barriers, company strategies, and emerging opportunities across the 7MM – Hunter Syndrome Treatment Market

Hunter Syndrome Epidemiology

In 2023, approximately 1,200 diagnosed prevalent cases of Hunter Syndrome were reported across the 7MM, with numbers expected to increase over time. The EU4 and the UK contributed around 350 cases, with Germany leading followed by the UK. The disorder primarily affects males, with symptom onset typically occurring between 2 and 4 years of age. Around two-thirds of patients develop cognitive impairment in the neuronopathic form, with symptoms emerging between 1 and 3 years. Patients are broadly categorized into severe (65–70%) and mild forms, although distribution varies across regions.

Segmentation includes:

• Total diagnosed prevalence
• Severity-based prevalence

Download the report to understand which factors are driving Hunter Syndrome epidemiology trends @ Hunter Syndrome Patient Population

Hunter Syndrome Drug Uptake and Pipeline Developments

Tividenofusp alfa (DNL310): Denali Therapeutics

Tividenofusp alfa (DNL310) is a fusion protein combining IDS with Denali’s proprietary Enzyme Transport Vehicle (ETV), enabling it to cross the blood-brain barrier through receptor-mediated transcytosis. This design allows for widespread delivery of IDS to both central nervous system tissues and peripheral organs, addressing neurological, cognitive, and physical symptoms of MPS II. The FDA granted Fast Track designation in March 2021, followed by Priority Medicines (PRIME) designation from the EMA in May 2022.

RGX-121: Regenxbio

RGX-121 is an investigational AAV-based gene therapy designed to treat MPS II by delivering the human IDS gene using the NAV AAV9 vector directly into the central nervous system. It represents the only late-stage therapy targeting neurocognitive outcomes in patients diagnosed before the age of two. In August 2025, REGENXBIO announced that the FDA extended the BLA review timeline for RGX-121, shifting the PDUFA date from November 9, 2025, to February 8, 2026.

Get a comprehensive view of drug uptake trends, clinical progress, regulatory designations, and market opportunities shaping the Hunter Syndrome market @ Hunter Syndrome Medication and FDA Approvals

Hunter Syndrome Market Drivers

• Significant unmet medical need, particularly for therapies addressing cognitive decline

• Advancements in gene therapy with promising clinical outcomes

• Favorable regulatory support, including orphan drug and rare pediatric disease designations

• Increased awareness leading to improved diagnosis rates

• Expanding pipeline with multiple late-stage candidates

• Enhanced patient support programs improving access and quality of care

Hunter Syndrome Market Barriers

• Extremely small patient population limits commercial viability

• High costs associated with existing and emerging treatments

• Limited effectiveness of current therapies in addressing neurological symptoms

• Variability in disease severity complicates treatment and clinical trials

• Challenges in recruiting pediatric patients for clinical studies

• Regulatory complexities surrounding gene therapy safety and long-term outcomes

Scope of the Hunter Syndrome Market Report

• Study Period: 2022–2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hunter Syndrome Companies: United Therapeutics, EUSA Pharma, Y-mAbs Therapeutics, Clarity Pharmaceuticals, and many others.
• Key Hunter Syndrome Therapies: UNITUXIN (dinutuximab), QARZIBA (dinutuximab beta), Omburtamab, SARTATE, and others.
• Hunter Syndrome Therapeutic Assessment: Hunter Syndrome current marketed and Hunter Syndrome emerging therapies
• Hunter Syndrome Market Dynamics: Hunter Syndrome market drivers and Hunter Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hunter Syndrome Unmet Needs, KOL’s views, Analyst’s views, Hunter Syndrome Market Access and Reimbursement

To learn more about Hunter Syndrome companies working in the treatment market, visit @ Hunter Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Introduction to the Hunter Syndrome Market Report
2. Executive Summary
3. SWOT Analysis
4. Patient Share Overview
5. Market Overview Snapshot
6. Disease Background
7. Epidemiology and Patient Population
8. Country-wise Patient Distribution
9. Current Treatment Practices
10. Unmet Needs
11. Emerging Therapies
12. Market Outlook
13. Country-level Market Analysis (2020–2036)
14. Market Access and Reimbursement
15. Market Drivers
16. Market Challenges
17. Appendix
18. Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a specialized healthcare consulting and market research firm focused on the life sciences sector, offering comprehensive solutions to support pharmaceutical companies in enhancing their business performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting